Enhanced secretion of CXCL12 by AML-MSCs and R-MSCs (in the latter case at lower levels and not statistically significant) versus D-MSCs indicates a substantial but not complete recovery of the secretion of this chemokine. This evidence concerns the gene CXCL12 and acute myeloid leukemia.